ClinicalTrials.gg
Status unknownNCT05347758Updated Apr 26, 2022

A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects

A Phase 1 interventional study of HRS-7535 and Placebo in Healthy Subjects, sponsored by Shandong Suncadia Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-26.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS-7535 in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 to 55 years of age (inclusive) healthy male or female of nonchildbearing potential;
  2. Body weight of at least 50 kg for male, and 45 kg for female; and (BMI) within the range of 19 to 28 kg/m2 (inclusive);
  3. Subjects (including partners) of are willing to use protocol specified effective methods of from screening to at least 6 months after the final dose of study drug;
  4. Able and willing to provide written and to comply with the study protocol;
  5. Physical examination, vital signs are normal or are judged not by the investigator;

Exclusion criteria

Exclusion Criteria:

  1. Participants with any abnormal results and judged by the investigator;
  2. ≥6.2%, fasting blood-glucose ≤3.9mmol/L (70mg/dL) or ≥6.1mmol/L(110mg/dL) at screening ;
  3. (ALT) or aspartate aminotransferase (AST) ≥2 x ; total ≥1.5 x ULN at screening;
  4. Abnormal that is clinically significant, or >450 msec;
  5. Positive test result of any of the following at screening: surface antigen (HBsAg), antibody, syphilis, or (HIV) antibody;
  6. Any (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years;
  7. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, history of pancreatitis or symptomatic gallbladder disease;
  8. History of gastric emptying anomalies (gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcer) ;
  9. Subject with major medical history of heart, liver, kidney, endocrine, digestive, blood, respiratory and genitourinary system or existing diseases of the above systems;
  10. Use any prescription drugs, non-prescription drugs, food supplements, vitamins and Chinese herbal medicines within 2 weeks before administration;
  11. Subject who received bariatric surgery or procedures, or use of weight-reducing drugs within 3 months prior to administration, or body weight change of more than ±10% within 3 months prior to administration;
  12. Use any drugs that may affect glucose metabolism were used within 1 month before administration.
  13. Suspected allergy to any ingredient in the study drug;
  14. Participation in clinical trials of any drug or medical device within 3 months before screening;
  15. History of regular alcohol consumption exceeding 14 drinks per week within 6 months before screening;
  16. More than 5 cigarettes per day or cigarettes within 3 months before screening;
  17. Subjects who consume alcoholic beverages, Seville oranges, grapefruit or juices, or products containing caffeine or xanthine (such as coffee, tea, cola drinks and chocolate) from 2 days before the start of study treatment;
  18. Strenuous exercise in 48 hours before treatment;
  19. Subjects with a history of drug abuse, drug dependence, or a positive drugs of abuse test, or a positive alcohol breath test before study drug administration;
  20. Donation or loss of blood of ≥ 200 mL within 1 month or of ≥ 400 mL within 3 months prior to the first dose of study drug;
  21. Subjects can't tolerate venipuncture;
  22. Subjects have special dietary requirements and cannot comply with the unified diet;
  23. Other conditions judged by the investigator to be not suitable to participate in the trial;
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: HRS-7535

    Drug: HRS-7535

  • Placebo comparator
    Group B

    Drug: Placebo

    Drug: Placebo

Interventions

  • Drug: HRS-7535

  • DrugPlacebo

    Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Number of adverse Events

    Number of adverse events per subject, including clinically relevant changes in physical examination, vital signs, laboratory tests and ECGs;

    Time frame: Day-2 to last follow-up

Secondary outcomes

  1. Pharmacokinetic (PK) profile of HRS-7535 - AUC0-t

    Area under the concentration-time curve from time zero to the last quantifiable time point t (AUC0-t);

    Time frame: pre-dose to 96 hours post-dose

  2. Pharmacokinetic (PK) profile of HRS-7535 - AUC0-∞

    Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞);

    Time frame: pre-dose to 96 hours post-dose

  3. Pharmacokinetic (PK) profile of HRS-7535 - Cmax

    Maximum observed concentration (Cmax);

    Time frame: pre-dose to 96 hours post-dose

  4. Pharmacokinetic (PK) profile of HRS-7535 - Tmax

    Time to maximum observed concentration (Tmax);

    Time frame: pre-dose to 96 hours post-dose

  5. Pharmacokinetic (PK) profile of HRS-7535 - t1/2

    Terminal elimination half-life (t1/2)

    Time frame: pre-dose to 96 hours post-dose

  6. Pharmacokinetic (PK) profile of HRS-7535 - CL/F

    Apparent clearance (CL/F);

    Time frame: pre-dose to 96 hours post-dose

  7. Pharmacokinetic (PK) profile of HRS-7535 - Vz/F

    Apparent volume of distribution (Vz/F);

    Time frame: pre-dose to 96 hours post-dose

  8. Pharmacokinetic (PK) profile of HRS-7535 - AUC0-τ,ss

    Area under the plasma concentration-time curve from time zero to tau at steady state (AUC0-τ,ss)

    Time frame: pre-last dose to 96 hours post- last dose

  9. Pharmacokinetic (PK) profile of HRS-7535 - AUC0-t,ss

    AUC0-t at steady state (AUC0-t,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  10. Pharmacokinetic (PK) profile of HRS-7535 - AUC0-∞,ss

    AUC0-∞ at steady state (AUC0-∞,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  11. Pharmacokinetic (PK) profile of HRS-7535 - Tmax,ss

    Tmax at steady state (Tmax,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  12. Pharmacokinetic (PK) profile of HRS-7535 - Cmax,ss

    Cmax at steady state (Cmax,ss)

    Time frame: pre- last doseto 96 hours post- last dose

  13. Pharmacokinetic (PK) profile of HRS-7535 - Ctrough,ss

    Ctrough at steady state (Ctrough,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  14. Pharmacokinetic (PK) profile of HRS-7535 - Cavg,ss

    Cavg at steady state (Cavg,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  15. Pharmacokinetic (PK) profile of HRS-7535 - DF

    Degree of fluctuation at steady state (DF)

    Time frame: pre- last dose to 96 hours post- last dose

  16. Pharmacokinetic (PK) profile of HRS-7535 - Vz,ss/F

    Vz/F at steady state (Vz,ss/F)

    Time frame: pre- last dose to 96 hours post- last dose

  17. Pharmacokinetic (PK) profile of HRS-7535 - CLss/F

    CL/F at steady state (CLss/F)

    Time frame: pre- last dose to 96 hours post- last dose

  18. Pharmacokinetic (PK) profile of HRS-7535 - t1/2,ss

    t1/2 at steady state (t1/2,ss)

    Time frame: pre- last dose to 96 hours post- last dose

  19. Pharmacodynamic (PD) profile of doses of HRS-7535 - blood glucose

    Time frame: pre-dose to 24 hours post-dose

  20. Pharmacodynamic (PD) profile of doses of HRS-7535 - insulin

    Time frame: pre-dose to 24 hours post-dose

  21. Pharmacodynamic (PD) profile of doses of HRS-7535 - C-peptide

    Time frame: pre-dose to 24 hours post-dose

  22. Pharmacodynamic (PD) profile of doses of HRS-7535 - glucagon

    Time frame: pre-dose to 24 hours post-dose

  23. Pharmacodynamic (PD) profile of doses of HRS-7535 - fructosamine

    Time frame: pre-dose up to 96 hours after the last dose

  24. PD profile of multiple doses of HRS-7535 - HbA1c

    Time frame: pre-dose up to 96 hours after the last dose

  25. PD profile of multiple doses of HRS-7535 - 5-points glucose profile

    Time frame: pre-dose up to 24 hours after the last dose

  26. PD profile of multiple doses of HRS-7535 - weight

    Time frame: pre-dose up to 96 hours after the last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2022; primary completion for Sep 2022, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 26, 2022
StartEst.
May 1, 2022
Primary completionEst.
Sep 18, 2022
CompletionEst.
Mar 15, 2023
Last update
Apr 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05347758
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
May 1, 2022 (estimated)
Primary completion
Sep 18, 2022 (estimated)
Completion
Mar 15, 2023 (estimated)
Last update
Apr 26, 2022

Study contacts

Yimei Xu
Contact
yimei.xu@hengrui.com
0518-82342973
Shujin Cheng
Contact
shujin.cheng@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safiglipron

Start the discussion